» Articles » PMID: 36482154

Natural Compounds Targeting Nuclear Receptors for Effective Cancer Therapy

Abstract

Human nuclear receptors (NRs) are a family of forty-eight transcription factors that modulate gene expression both spatially and temporally. Numerous biochemical, physiological, and pathological processes including cell survival, proliferation, differentiation, metabolism, immune modulation, development, reproduction, and aging are extensively orchestrated by different NRs. The involvement of dysregulated NRs and NR-mediated signaling pathways in driving cancer cell hallmarks has been thoroughly investigated. Targeting NRs has been one of the major focuses of drug development strategies for cancer interventions. Interestingly, rapid progress in molecular biology and drug screening reveals that the naturally occurring compounds are promising modern oncology drugs which are free of potentially inevitable repercussions that are associated with synthetic compounds. Therefore, the purpose of this review is to draw our attention to the potential therapeutic effects of various classes of natural compounds that target NRs such as phytochemicals, dietary components, venom constituents, royal jelly-derived compounds, and microbial derivatives in the establishment of novel and safe medications for cancer treatment. This review also emphasizes molecular mechanisms and signaling pathways that are leveraged to promote the anti-cancer effects of these natural compounds. We have also critically reviewed and assessed the advantages and limitations of current preclinical and clinical studies on this subject for cancer prophylaxis. This might subsequently pave the way for new paradigms in the discovery of drugs that target specific cancer types.

Citing Articles

NR0B2 Is a Key Factor for Gastric Diseases: A GEO Database Analysis Combined with Drug-Target Mendelian Randomization.

Li Z, Xu L, Huang D, Li C, Haenen G, Zhang M Genes (Basel). 2024; 15(9).

PMID: 39336801 PMC: 11431353. DOI: 10.3390/genes15091210.


Tackling exosome and nuclear receptor interaction: an emerging paradigm in the treatment of chronic diseases.

Aswani B, Hegde M, Vishwa R, AlQahtani M, Abbas M, Almubarak H Mil Med Res. 2024; 11(1):67.

PMID: 39327610 PMC: 11426102. DOI: 10.1186/s40779-024-00564-1.


In silico analysis of polyphenols modulate bovine PPARγ to increase milk fat synthesis in dairy cattle via the MAPK signaling pathways.

Safdar M, Hassan F, Khan M, Khan A, Junejo Y, Ozaslan M J Anim Sci. 2024; 102.

PMID: 39210246 PMC: 11551727. DOI: 10.1093/jas/skae248.


Nuclear receptors in ovarian cancer: changing paradigms in cancer therapeutics.

Sajeev A, BharathwajChetty B, Manickasamy M, AlQahtani M, Abbas M, Shakibaei M Front Oncol. 2024; 14:1383939.

PMID: 39077471 PMC: 11284039. DOI: 10.3389/fonc.2024.1383939.


Curcumin in Cancer Prevention: Insights from Clinical Trials and Strategies to Enhance Bioavailability.

Alam S, Lee J, Sahebkar A Curr Pharm Des. 2024; 30(23):1838-1851.

PMID: 38808709 DOI: 10.2174/0113816128303514240517054617.


References
1.
Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Arora L, Kumar A, Arfuso F, Chng W, Sethi G . The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers (Basel). 2018; 10(9). PMC: 6162647. DOI: 10.3390/cancers10090327. View

4.
Bushweller J . Targeting transcription factors in cancer - from undruggable to reality. Nat Rev Cancer. 2019; 19(11):611-624. PMC: 8820243. DOI: 10.1038/s41568-019-0196-7. View

5.
Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Ranjbar A . Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?. Cancer Lett. 2021; 509:63-80. DOI: 10.1016/j.canlet.2021.03.025. View